Clinical trial data and post-marketing surveillance have documented gastrointestinal complaints in a substantial proportion of patients, with nausea being the most frequent (reported in 1540% of patients depending on the specific agent and dose), followed by vomiting, diarrhoea, constipation, and dyspepsia
While some people notice a decreased appetite within the first four weeks, significant weight loss typically occurs over several months
Share: The growing popularity of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus has largely been driven by their ability to help people lose weight, improve blood sugar control, and reduce the risk of cardiovascular disease
Liraglutide Both semaglutide and liraglutide mimic the signals, normally triggered by GLP-1, that inhibit appetite
: , -